Letter from the CEO, SciBase April 2019
Dear SciBase shareholders,At SciBase we have been very focused on two key development projects and a market launch over the last months, which explains the lack of CEO letters - my apologies! Now that we have come some way on the projects, I thought I’d take the chance to describe what has happened so far, and what we see coming in the near future. The updated measurement method, Nevisense 3.0 Much of 2018 was spent overhauling the Nevisense measurement method for melanoma. Though we knew our method worked, we also knew that customers felt it involved too many steps and the time it